Dentsply Sirona (NASDAQ: XRAY) and Biolase (NASDAQ:BIOL) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Institutional and Insider Ownership
97.8% of Dentsply Sirona shares are held by institutional investors. Comparatively, 36.2% of Biolase shares are held by institutional investors. 1.9% of Dentsply Sirona shares are held by insiders. Comparatively, 3.2% of Biolase shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Dentsply Sirona pays an annual dividend of $0.35 per share and has a dividend yield of 0.7%. Biolase does not pay a dividend. Dentsply Sirona pays out 13.2% of its earnings in the form of a dividend.
This table compares Dentsply Sirona and Biolase’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Dentsply Sirona has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Biolase has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500.
Earnings & Valuation
This table compares Dentsply Sirona and Biolase’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Dentsply Sirona||$3.99 billion||2.85||-$1.55 billion||$2.66||18.81|
|Biolase||$46.93 million||0.72||-$16.85 million||N/A||N/A|
Biolase has lower revenue, but higher earnings than Dentsply Sirona.
This is a breakdown of recent ratings and price targets for Dentsply Sirona and Biolase, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Dentsply Sirona currently has a consensus price target of $67.00, suggesting a potential upside of 34.19%. Biolase has a consensus price target of $2.50, suggesting a potential upside of 681.25%. Given Biolase’s stronger consensus rating and higher probable upside, analysts plainly believe Biolase is more favorable than Dentsply Sirona.
About Dentsply Sirona
DENTSPLY SIRONA Inc. designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials. In addition, it provides dental technology products, including dental implants and related scanning equipment, treatment software, and orthodontic appliances for dental practitioners and specialist, and dental laboratories; and dental equipment, such as treatment centers, imaging equipment, and computer aided design and machining systems for dental practitioners and laboratories. Further, the company offers healthcare consumable products, such as urology catheters, various surgical products, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers to dentists, dental hygienists, dental assistants, dental laboratories, and dental schools; and urology products directly to patients, as well as through distributors to urologists, urology nurses, and general practitioners. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in York, Pennsylvania.
BIOLASE, Inc., a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine in the United States and internationally. The company offers Waterlase dental laser systems for cutting soft and hard tissue; and diode laser systems, which are used to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of dental procedures, such as cosmetic, restorative, and complex surgical applications. The company also markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and CAD/CAM intra-oral scanners. Its dental imaging products comprise 3Shape Trios intraoral scanner and digital impression systems for high-speed digital 3-D picture taking; Galaxy BioMill CAD/CAM system that enables dental practitioners to design, scan, mill, and finish crowns, inlays, and veneers inside the dental office; and CEFLA NewTom VGi and VG3 3-D cone beam computed tomography devices. In addition, the company manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces. It sells its products primarily to dentists in general practice through its field sales force and distributor network. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.
Receive News & Ratings for Dentsply Sirona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dentsply Sirona and related companies with MarketBeat.com's FREE daily email newsletter.